Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection.

Larsson, Charlotte U; Holmgren, Jan; Lindahl, Gunnar; Bergquist, Charlotta

Published in:
Infection and Immunity

DOI:
10.1128/IAI.72.2.1184-1187.2004

Published: 2004-01-01

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection

Charlotte Larsson, Jan Holmgren, Gunnar Lindahl, and Charlotta Bergquist

Department of Medical Microbiology, Dermatology and Infection, Lund University, Lund, Sweden, and Department of Medical Microbiology and Immunology, Göteborg University, Göteborg, Sweden

Received 10 September 2003/Returned for modification 9 October 2003/Accepted 14 November 2003

Intranasal immunization of mice with Rib, a cell surface protein of group B streptococcus (GBS), conjugated to or simply coadministered with the recombinant cholera toxin B subunit, induces systemic immunoglobulin G (IgG) and local IgA antibody responses and confers protection against lethal GBS infection. These findings have implications for the development of a human GBS vaccine.

Several approaches have been tried in an attempt to design an efficient vaccine against group B streptococcal (GBS) disease, and possible vaccine components include capsular polysaccharides and cell surface proteins of GBS (2, 8, 9, 12, 16, 17, 20, 27). Mucosal immunization is an attractive strategy, since it is noninvasive and has the potential to induce both systemic and local immune responses (3, 14, 22). Indeed, it should be advantageous to use a GBS vaccine that not only induces protective immunoglobulin G (IgG) antibodies that can be transplacentally transferred to the fetus but also induces mucosal antibodies that prevent genital colonization of the mother and thereby prevent transfer of the bacteria to the fetus.

Some human and animal studies have focused on antibodies to GBS at the female genital mucosa (8–12, 24). Although, the role of these local antibodies in the pathogenesis of GBS infection is not clear, it seems reasonable to assume that they may to some extent protect against colonization with GBS (10). It has been reported that mucosal immunization with GBS polysaccharides or inactivated GBS bacteria induces systemic and local antibody responses in mice (8, 9, 12, 24). However, there is no previous report on mucosal immunization with purified GBS proteins.

Earlier studies have shown that parenterally administered cell surface proteins of GBS elicit a systemic IgG response and confer protection against experimental GBS infection (1, 6, 17, 18, 20). This made it of interest to examine if these proteins could also be used in a mucosal GBS vaccine. In the present study, Rib, a well-characterized GBS surface protein that is expressed by many strains causing invasive neonatal infection (17, 25, 26), was combined with recombinant cholera toxin B subunit (CTB) and administered intranasally (i.n.) to mice. The systemic and local IgG and IgA responses were examined. In addition, the protective capacity of this mucosal vaccination was evaluated by lethal intraperitoneal (i.p.) challenge with GBS.

Preparation of conjugate vaccine. The Rib protein was isolated from the high-virulence type III strain BM110 (21, 25) by several purification steps and was free of contaminating polysaccharides (17, 25). Recombinant CTB was purified from Vibrio cholerae strain 358 (19). The Rib protein was conjugated to CTB using N-succinimidyl 3-(2-pyridyldithio)propioninate (SPDP; Pharmacia AB, Uppsala, Sweden) as a bifunctional coupling reagent. SPDP was added to both proteins according to the manufacturer’s instructions, using pH 8.5 for Rib and pH 7.5 for CTB. A similar method has been used for coupling polysaccharides to CTB and is described in detail elsewhere (4, 5). A 10-fold molar excess was used for Rib, and a 3-fold molar excess was used for CTB. The 2-pyridyl disulfide-containing Rib was then reduced using 50 mM dithiothreitol, and the excess 2-pyridyl disulfide and dithiothreitol was removed using a Sephadex G25 prepacked PD10 column (Pharmacia AB, Uppsala, Sweden). The two derivatized proteins were mixed and allowed to react overnight at room temperature. The conjugate was purified using a Superdex 200 10/30 column connected to a BioLogic WorkStation (Bio-Rad). The fractions containing the highest-molecular-weight material were collected, pooled, and concentrated using an Amicon stirred concentration cell (Amicon). The conjugate was tested by enzyme-linked immunosorbent assay (ELISA), and both CTB and Rib were detected. The Lowry protein determination assay was used to measure the total protein content of the conjugate. However, the exact proportion of each protein could not be determined. The conjugate was stored at 4°C with 0.005% Merthiolat (Kebo AB, Stockholm, Sweden) as a preservative.

Immunizations and antibody responses. Five groups with four 10-week-old C3H/HeN female mice (Charles River, Sulzfeld, Germany) in each group were immunized i.n. with either of the following vaccines: protein Rib conjugated to CTB (Rib-CTB) (8 μg), Rib mixed with CTB (Rib+CTB) (4 μg plus 4 μg), Rib alone (Rib) (4 μg), CTB alone (CTB) (4 μg), or phosphate-buffered saline (PBS) three times 2 weeks apart. One group with four mice received 5 μg of Rib subcutaneously (s.c.) and 4 weeks later a booster of 2.5 μg s.c. The antigens were diluted in PBS to a volume of 25 μl for i.n. administration and 150 μl for s.c. administration, respectively. The mice were lightly anesthetized with methoxyflurane (Methofane) (Mallin-
The titers of antibody are presented as the antilog of the geometric mean and range. Titer of IgG, geometric mean (range) in serum were 6,959 (1,772–27,258) for Rib-CTB i.n., 10,342 (6,288–14,998) for Rib s.c., 36 (36–87) for Rib-CTB i.n., 8 (4–18) for Rib i.n., 3 for Rib s.c., and 3 for CTB i.n. Most of these IgG antibodies were produced, according to the observations made in the previous control experiment referred to above (13).

Protection against lethal GBS infection. Groups of 15 mice were vaccinated with Rib-CTB i.n., Rib+CTB i.n., Rib s.c., or PBS i.n., as described above. Two weeks after the booster mice were challenged i.p. with a ~90% lethal dose of log-phase bacteria (BM110) diluted in 0.5 ml of Todd-Hewitt broth. Deaths were recorded daily for 7 days (17). Vaccine efficacy (or protective efficacy) was calculated by the following formula: (mortality in nonvaccinated − mortality in vaccinated)/(mortality in nonvaccinated). Statistical significance was estimated by Fisher's exact test and confidence intervals (CI). The confidence level was set at 0.95. A P value of less than 0.05 was considered statistically significant.

Immunization with CTB−Rib or CTB+Rib provided protection against lethal infection with the GBS type III strain BM110 expressing the Rib protein (Fig. 1). Ten of fifteen mice vaccinated with Rib-CTB i.n. and 12 of 15 mice vaccinated with Rib+CTB survived a challenge with a lethal i.p. dose of GBS. The protective efficacy for Rib-CTB was 55% (CI, 37 to 73; P = 0.03) and 73% (CI, 57 to 89; P = 0.005) for Rib+CTB. In agreement with previous reports (17, 18), s.c. vaccination with the Rib protein protected against lethal GBS infection. We observed, however, that even though the amount of the Rib protein used for s.c. immunization was reduced and was given without adjuvant, it still induced sufficient immunity to confer

---

**TABLE 1.** Titers of Rib-specific IgG in serum after immunization with different vaccine compositions

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Route of immunization</th>
<th>Titer of IgG, geometric mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rib-CTB</td>
<td>i.n.</td>
<td>6,959 (1,772–27,258)</td>
</tr>
<tr>
<td>Rib+CTB</td>
<td>i.n.</td>
<td>10,342 (6,288–14,998)</td>
</tr>
<tr>
<td>Rib s.c.</td>
<td></td>
<td>86 (40–261)</td>
</tr>
<tr>
<td>CTB i.n.</td>
<td></td>
<td>4 (3–11)</td>
</tr>
<tr>
<td>Rib s.c.</td>
<td></td>
<td>2,243 (640–4,030)</td>
</tr>
</tbody>
</table>

* Mice (four per group) were immunized thrice with Rib-CTB, Rib+CTB, Rib, or CTB i.n. or twice with Rib s.c.

**TABLE 2.** Titers of Rib-specific IgA in serum and genital tissue extract after immunization with different vaccine compositions

<table>
<thead>
<tr>
<th>Vaccine tissue</th>
<th>Route of immunization</th>
<th>Titer of IgA, geometric mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rib-CTB i.n.</td>
<td></td>
<td>53 (36–87)</td>
</tr>
<tr>
<td>Rib+CTB i.n.</td>
<td></td>
<td>8 (4–18)</td>
</tr>
<tr>
<td>Rib i.n.</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>CTB i.n.</td>
<td></td>
<td>4 (3–9)</td>
</tr>
<tr>
<td>Rib s.c.</td>
<td></td>
<td>4 (3–9)</td>
</tr>
</tbody>
</table>

* Mice (four per group) were immunized thrice with Rib-CTB, Rib+CTB, Rib or CTB i.n. or twice with Rib s.c. The genital tissue was extracted with 2% saponin-PBS.

* Only three sera were available for analysis of IgA.
complete protection against lethal GBS infection ($P = 0.00002$) (Fig. 1).

Conclusions. Intranasal immunization of mice with the Rib protein and CTB seems to induce systemic and local antibody responses and to confer protective immunity against GBS infection. The titers of IgG induced by immunization with Rib+CTB and Rib-CTB i.n. were higher than the titers induced by Rib s.c. (Table 1). Yet, the protective efficacy for Rib given s.c. was higher than for Rib+CTB and Rib-CTB given i.n. (Fig. 1). However, s.c. injection and mucosal application represent presentation of the vaccine antigen (Rib) to the immune system in two different ways. In addition, the mucosal route included an adjuvant (CTB). These differences may have resulted in vaccine-induced antibodies with different avidities for the Rib protein. It seems possible that the conjugation process may be further optimized, resulting in a more immunogenic preparation.

We observed a wide range of antibody responses in some mouse groups (Tables 1 and 2). This variable antibody response was concordant with the individual response patterns for antibodies in both serum and genital tissue. However, since the number of mice in each group was small, it is difficult to draw general conclusions about the levels of antibody response to the different vaccines. The local antibody levels in the female genital tract vary with the stage of the estrous cycle, and it has been shown that pretreatment of mice with progesterone before mucosal immunizations increases the number of antibody-secreting cells in the genital tract not only in response to local vaginal immunization but also in response to i.n. immunization (13). Hence, the individual variation and the level of the antibody response might have been different in the present experiment had the mice been pretreated with hormones.

A relevant question is how the antibody response would be in humans. Although only vaccination studies with humans will give the full answer to this question, some encouraging observations have been published. In one study rhesus monkeys (Macaca mulatta) were immunized i.n. with a streptococcal protein antigen (AgI/II) either chemically conjugated to or mixed with CTB, which resulted in both systemic and local IgG and IgA responses to the vaccine antigens (23). Since these nonhuman primates are phylogenetically close to humans, it seems possible that humans would respond similarly to i.n. immunization with vaccines composed of bacterial protein and CTB. Further, i.n. immunization with CTB in humans has stimulated strong systemic as well as respiratory and vaginal mucosal antibody responses (3, 14, 22). Moreover, recent studies of naturally acquired antibodies to GBS cell surface proteins in different human populations have indicated that antibodies to GBS cell surface proteins are prevalent (10, 15), indicating that these protein antigens indeed are immunogenic also in humans.

The majority of clinically important GBS strains express either of the two proteins Rib or α (17, 25). Previously, we have shown that it is possible to include these two GBS cell surface proteins in a vaccine and elicit protective immunity in mice without any sign of immunogenic competition between the vaccine antigens (18). We conclude that i.n. immunization with a vaccine containing cell surface proteins from GBS strains that are prevalent among pregnant women may be an alternative strategy in the ongoing efforts to design an efficient vaccine against neonatal GBS disease.

This work was supported by grants from the Swedish Research Council (Medicine), the Meningitis Research Foundation (United Kingdom), Sida-SAREC’s programme for research on AIDS and related sexually transmitted infections, the “Förenade Liv” Mutual Group Life Insurance Company, the Swedish Society for Medical Research, the Royal Physiographic Society in Lund, and the trusts of Jerring, Kock, and Osterlund.

We thank Margaretha Stålhammar-Carlelalm for her help and for purified protein Rib, and we thank Gun Wallerström for laboratory assistance.

REFERENCES


FIG. 1. Protection against lethal GBS infection by i.n. immunization with the Rib protein chemically conjugated to CTB (Rib-CTB) (□) or simply coadministered with CTB (Rib+CTB) (■) and s.c. immunization with Rib alone (●). Sham-immunized mice received PBS i.n. (○). The vaccinated mice, 15 in each group, were challenged i.p. with a ~90% lethal dose of GBS strain BM110. Deaths were recorded daily for 7 days. Fisher’s exact test was used to calculate $P$ values.


Editor: D. L. Burns